Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bayer Aktienges ADR (OP: BAYRY ) 7.830 -0.010 (-0.13%) Streaming Delayed Price Updated: 3:59 PM EDT, Aug 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Bayer Aktienges ADR < Previous 1 2 3 4 5 6 Next > BAYRY Stock Earnings: Bayer Meets EPS, Beats Revenue for Q2 2024 August 06, 2024 BAYRY stock results show that Bayer met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. Via InvestorPlace Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer July 25, 2024 Australian judge dismisses class action lawsuit against Bayer for Roundup causing cancer. Ruling supports company's stance that product is safe. Via Benzinga Topics Lawsuit Exposures Financial Glyphosate Legal ScottsMiracle-Gro Stock Blooms After Investor Day Optimism July 23, 2024 Lawn and garden products manufacturer ScottsMiracle-Gro Co. (NYSE: SMG) stock surged on its Investor Day update ahead of fiscal Q3 2024 earnings release. Via MarketBeat Topics Cannabis Exposures Cannabis 3 Longevity Stocks to Buy for Anti-Aging Breakthroughs July 08, 2024 Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery. Via InvestorPlace 3 Small-Cap Stocks With Explosive 2X Growth Potential July 08, 2024 Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. Via InvestorPlace Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M June 05, 2024 Pennsylvania judge cuts Bayer's $2.25 billion Roundup verdict to $400 million. Both Bayer and plaintiff plan appeals in the ongoing cancer litigation. Via Benzinga Exposures Glyphosate Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership June 01, 2024 Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in... Via Talk Markets European Equities Close Higher As Traders Bank On Imminent ECB Rate Cut: What's Driving Markets Monday? May 27, 2024 European equities up, ECB likely to cut rates in June, traders confident. Euro slightly higher. Top performers: RWE, Bayer, VW, Enel, Iberdrola. Via Benzinga After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February May 24, 2024 Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. Via Benzinga Topics Data Breach Exposures Information Security Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval May 17, 2024 Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo. Via Benzinga Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game May 16, 2024 On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... Via Benzinga BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q1 2024 May 14, 2024 BAYRY stock results show that Bayer beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch May 10, 2024 Unlock the potential of AI in pharmaceuticals. With AI's help, the pharma industry could see $60B-$110B in annual economic value. Dive into the future of drug discovery and clinical development with... Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Bayer's Monsanto Scores Legal Victory as $185M Verdict Overturned May 02, 2024 Bayer's Monsanto unit secures a significant legal victory as Washington state appeals court overturns $185 million verdict over chemical contamination. This highlights broader legal battles over PCBs... Via Benzinga Exposures Glyphosate Alphabet, Nasdaq, Spotify, Teck Resources And A Major Financial Stock On CNBC's 'Final Trades' April 10, 2024 On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Nasdaq, Inc. (NASDAQ: NDAQ) is Via Benzinga Google Partners With European Conglomerate Bayer For New AI-Powered Solutions For Radiologists April 09, 2024 Unlock AI-powered radiology solutions with Bayer AG and Google Cloud collaboration. Accelerate medical imaging innovations with gen AI tools for faster diagnoses. Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Wondering Where To Find An Over 7% Annual Return? Check Out These 10 Investment-Grade Corporate Bonds April 05, 2024 Corporate bonds offer yield opportunities and diversification away from equity investments. Investment-grade bonds are safer but lower yield, while high-yield bonds offer higher returns but from... Via Benzinga Topics Bonds Exposures Debt Markets Bayer-Backed Boundless Bio Falls After IPO March 31, 2024 Shares of Boundless Bio fell almost 10% after raising about $100 million in the company's initial public offering. Bayer is one of the biggest investors for the therapeutics company. Via Talk Markets Dyadic Intl. Inc. (NASDAQ: DYAI) Potential Strategic Alliances with Future of Foods Boosts Stock as Key Conference Looms March 19, 2024 Via AB Newswire Topics Supply Chain Exposures Supply Chain Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant March 19, 2024 Bayer's Phase 3 study OASIS 3 findings on elinzanetant, a promising non-hormonal treatment for menopausal hot flashes. Results show significant reduction in symptoms over 12 weeks, marking a potential... Via Benzinga Exposures Product Safety German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits March 14, 2024 Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the controversial tactic and its potential implications. Via Benzinga Topics Bankruptcy Lawsuit Exposures Financial Glyphosate Legal BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q4 2023 March 05, 2024 BAYRY stock results show that Bayer beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. Via InvestorPlace Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges March 05, 2024 Bayer charts strategic course amid structural evaluation. CEO Bill Anderson addresses group's challenges, prioritizing performance and flexibility. The company's focus and fiscal outlook for 2024. Via Benzinga Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits March 04, 2024 Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. Via InvestorPlace What's Going On With BridgeBio Pharma Stock On Monday? March 04, 2024 BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted. Via Benzinga Exposures Product Safety BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out? March 04, 2024 BridgeBio will receive a tiered royalty on sales that begins at the low-30% range. Via Investor's Business Daily Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? March 01, 2024 On the leading edge of rare disease treatment and therapy is where you will find these Cathie Wood biotech stocks. Via InvestorPlace 3 Overextended Stocks That Need to Slash Their Dividends ASAP February 27, 2024 The most common attribute of overextended stocks other than carrying too much debt is dividends that are too big. Via InvestorPlace MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential February 22, 2024 MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. Via Talk Markets Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million February 11, 2024 I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China... Via Talk Markets < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.